Company profile
Lakefront Biotherapeutics NV
NASDAQ:LKFTBiotechnology: Pharmaceutical Preparations
Drug pipeline (16)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZIRITAXESTAT | phase3 | — | 8 | completed, terminated |
| ALDUMASTAT | phase2 | — | 3 | no active trials |
| Cadefrecitinib | phase2 | — | 8 | no active trials |
| FILGOTINIB HYDROCHLORIDE | phase2 | — | 11 | no active trials |
| GALICAFTOR | phase2 | — | 5 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (115)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03725852 | phase2 | completed | 2018-09-27 | 2020-07-21 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) |
| NCT03733444 | phase3 | terminated | 2018-11-05 | 2021-03-30 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care |
| NCT03798366 | phase2 | completed | 2019-01-14 | 2020-05-21 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis |
| NCT03711162 | phase3 | terminated | 2018-11-28 | 2021-03-30 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care |
| NCT03976648 | phase2 | terminated | 2019-07-18 | 2021-04-13 | Lakefront Biotherapeutics NV | A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis |
FDA applications (0)
No records yet.